Disodium clodronate in the treatment of diffuse sclerosing osteomyelitis (DSO) of the mandible
| Autor: | Christian Lindqvist, B.-M. Lindströrm, M. Montonen, L. Pylkkären, E. Kalso |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Adult
Male medicine.medical_specialty Bone disease medicine.medical_treatment Analgesic Placebo Statistics Nonparametric 03 medical and health sciences 0302 clinical medicine Double-Blind Method Facial Pain immune system diseases Humans Medicine Mandibular Diseases Aged Pain Measurement Analysis of Variance Chemotherapy business.industry Osteomyelitis 030206 dentistry Analgesics Non-Narcotic Middle Aged respiratory system Bisphosphonate medicine.disease respiratory tract diseases 3. Good health Surgery Treatment Outcome Otorhinolaryngology 030220 oncology & carcinogenesis Anesthesia Chronic Disease Injections Intravenous Clodronic acid Female Clodronic Acid Oral Surgery Osteitis business medicine.drug |
| Zdroj: | International Journal of Oral and Maxillofacial Surgery. 30:313-317 |
| ISSN: | 0901-5027 |
| DOI: | 10.1054/ijom.2001.0061 |
| Popis: | Diffuse sclerosing osteomyelitis (DSO) of the mandible is a chronic condition, the cause of which is not known. Jaw pain, occurring irregularly, is a typical symptom. The aim of the study was to assess the effectiveness of disodium clodronate for relieving pain in patients with DSO. Disodium clodronate is a bisphosphonate used to treat diseases of bone and calcium metabolism. Ten DSO patients experiencing pain received disodium clodronate or placebo intravenously on a randomized double-blind basis. Both minimum (300 mg) and maximum (900 mg) doses were well tolerated. Disodium clodronate administration did not result in better immediate pain relief than placebo administration. However, 6 months after treatment there was a statistically significant difference in pain intensity between the groups, with the disodium clodronate group experiencing significantly less pain. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect